Order Article Reprints

Zambrano-Vásquez OR, Cortes-Camacho F, Cabrera-Angeles JC, Hernández-Alba AL, García-Arroyo FE, Castañeda-Sánchez JI, Aréchaga-Ocampo E, Aparicio-Trejo OE, Valle-Mondragón LD, Martínez-Olivares CE, et al. The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model. International Journal of Molecular Sciences. 2025; 26(18):9010. https://doi.org/10.3390/ijms26189010

Zambrano-Vásquez, Oscar René, Fernando Cortes-Camacho, Juan Carlos Cabrera-Angeles, Ana Lilia Hernández-Alba, Fernando Enrique García-Arroyo, Jorge Ismael Castañeda-Sánchez, Elena Aréchaga-Ocampo, Omar Emiliano Aparicio-Trejo, Leonardo Del Valle-Mondragón, Constanza Estefanía Martínez-Olivares, and et al. 2025. "The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model" International Journal of Molecular Sciences 26, no. 18: 9010. https://doi.org/10.3390/ijms26189010

Zambrano-Vásquez, O. R., Cortes-Camacho, F., Cabrera-Angeles, J. C., Hernández-Alba, A. L., García-Arroyo, F. E., Castañeda-Sánchez, J. I., Aréchaga-Ocampo, E., Aparicio-Trejo, O. E., Valle-Mondragón, L. D., Martínez-Olivares, C. E., Hernández-Pando, R., Sánchez-Lozada, L. G., & Osorio-Alonso, H. (2025). The Combination Empagliflozin/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model. International Journal of Molecular Sciences, 26(18), 9010. https://doi.org/10.3390/ijms26189010